文献速递其他结缔组织病

澳大利亚队列研究:系统性硬化症患者的面部美容治疗使用情况

Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-08-17

该研究纳入澳大利亚硬皮病队列中241例完成问卷的系统性硬化症患者,描述其面部美容治疗的使用与体验。119例(49.4%)曾考虑或使用过美容治疗,55例(22.8%)至少使用过一种;共报告159种治疗,64.2%针对SSc相关面部改变,73.0%报告主观改善,15.7%报告不良事件且多为轻度。

要点

  • 241例SSc患者中22.8%至少使用过一种面部美容治疗,49.4%曾考虑使用。
  • 考虑但未使用的主要原因为费用(50.0%)和安全顾虑(37.5%)。
  • 159种治疗中64.2%针对SSc相关面部改变,73.0%报告主观改善,不良事件多为轻度。

核心结论

  • SSc患者广泛使用面部美容治疗,既针对SSc相关也针对非SSc相关面部改变,多数使用者报告主观改善且严重不良事件少见。

研究设计与样本

  • 澳大利亚硬皮病队列研究,纳入三家澳大利亚公立三级医院和一家私人诊所的SSc患者,邀请完成去标识化问卷,采用描述性统计分析。

主要发现

  • 616例受邀患者中241例完成问卷,119例(49.4%)曾考虑或使用过面部美容治疗,55例(22.8%)至少使用过一种。
  • 考虑但未使用者中32例(50.0%)因费用、24例(37.5%)因安全顾虑未进行。
  • 共报告159种面部美容治疗,包括外用化妆品(42.1%)、注射治疗(32.1%)、能量设备或激光治疗(22.6%)和手术(2.5%)。
  • 159种治疗中64.2%针对SSc相关面部改变,116种(73.0%)报告主观改善,25种(15.7%)报告不良事件且多为轻度。

临床怎么用

  • 风湿免疫科医生应主动询问SSc患者面部美容治疗的使用情况,关注费用与安全顾虑对决策的影响。
  • 对考虑美容治疗的患者,可告知多数使用者报告主观改善且严重不良事件少见,同时需个体化评估风险。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterize patient engagement and experiences with cosmetic therapies for SSc-related and non-SSc-related facial changes. METHODS: Patients with SSc enrolled in the Australian Scleroderma Cohort Study at three Australian public tertiary hospitals and one private practice were invited to complete a de-identified questionnaire. Participants were asked about their engagement and perceived outcomes with cosmetic therapies including topical cosmeceuticals, injectable therapies, energy-based devices or laser therapies, and surgical procedures for facial changes. Descriptive statistics were analyzed. RESULTS: Of the 616 patients invited, 241 participants completed the questionnaire with 119 responders (49.4%) reporting that they had previously or were currently considering a facial cosmetic therapy and 55 (22.8%) reporting use of at least one therapy. Of those who considered but did not go ahead with a therapy, 32 (50.0%) did not proceed due to cost and 24 (37.5%) due to safety concerns. A total of 159 facial cosmetic therapies were reported. These included topical cosmeceuticals (42.1%), injectable therapies (32.1%), energy-based devices or laser therapies (22.6%), and surgical procedures (2.5%). Almost two thirds (64.2%) were performed for SSc-related facial changes. Responders reported perceived improvement with 116 cosmetic therapies (73.0%) and adverse events for 25 (15.7%). Most adverse events were mild. CONCLUSION: Patients with SSc engage broadly with cosmetic therapies for both SSc-related and non-SSc-related facial changes. Most users reported subjective improvement, and few serious adverse effects were reported.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Warren Z, Apostolopoulos D, Ngian GS, et al. Facial Cosmetic Therapy Use Among Patients With Systemic Sclerosis: An Australian Cohort Study. Arthritis Care Res (Hoboken). 2026. PMID: 42605882. doi:10.1002/acr.80143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。